MicroPort completed its initial public offering on the Hong Kong Stock Exchange in 2010 and has since established multiple specialized subsidiaries focused on distinct therapeutic areas, with several completing separate public listings. Recognized as one of the global Medtech Big 100 companies,[3] MicroPort's coronary intervention products have been implanted in over 10 million patients globally since its founding, with devices distributed globally in over 90 countries across.[4]
History
MicroPort was founded in 1998 by Zhaohua Chang, who currently serves as CEO, chairman, and Director.[5] The company rose to prominence from the early success of its coronary stent line due its focus on serving the needs of the Chinese device market.[6][7] It is now one of the top global manufacturers of cardiac interventional devices.[8] Notably, it produces the world's first and only commercially available targeted drug eluting stent system, which uses a significantly reduced amount of drug than traditional drug eluting stents while maintaining effectiveness.[9][10][11][12] As of early 2018, MicroPort is one of few medical device companies still developing a commercial coronary bioresorbable stent with ongoing clinical trials.[13][14][15]
Beginning in the 2010s, MicroPort has rapidly expanded around the world via international acquisitions to other medical device industries, including orthopedics and cardiac rhythm management.[16][17]
In 2014, MicroPort expanded operations in the United States by acquiring Wright Medical's OrthoRecon business to become the 6th largest international producer of orthopedic devices at the time.[18] MicroPort's orthopedic business is based in Arlington, Tennessee and in 2018 has expanded its business into India.[19]
In 2018, MicroPort and LivaNova closed the sale of LivaNova's cardiac rhythm management business for $190M.[17]
In 2018, MicroPort purchased Lombard Medical, a UK-based endovascular device company, from bankruptcy after it defaulted on loans in early 2018.[20]
In 2021, MicroPort purchased Hemovent GmbH, a German-based manufacturer of extracorporeal life support systems.[21]
These acquisitions have been followed up with substantial local investment, including a US$398 Million investment in 2019 to develop pacemakers and defibrillators in France.[22]
In 2022, MicroPort established its US headquarters in Irvine, California with facilities that include a manufacturing base and innovation center.[23] As of 2022, its principal business is valued at over US$6.5 Billion.[24]
In 2025, the Toumai Tele-Robotic Surgical System received NMPA approval as the first tele-operated surgical robotic system authorized for commercial clinical use, supporting multiple communication infrastructures including 5G, broadband, dedicated fiber, and satellite links.[25] The system has been used in a program of remote robotic telesurgery cases, including procedures performed in Angola with surgeons operating the robot from Florida as part of a FDA investigational device exemption (IDE) clinical trial on long-distance telesurgery.[26][27][28]
Business operations
MicroPort operates through multiple business platforms spanning cardiovascular and structural heart intervention, cardiac rhythm management, electrophysiology, neurovascular and endovascular intervention, orthopedics, and surgical robotics, with several operating as separately listed subsidiaries.
Interventional cardiology
MicroPort’s interventional cardiology business encompasses coronary stents, bioresorbable vascular scaffolds, peripheral vascular devices, and associated delivery systems for percutaneous coronary intervention (PCI). The company’s coronary stent portfolio includes the Firebird, Firehawk, and Firesorb product families. Firehawk, described by the company as the world’s first “targeted” drug-eluting stent, delivers sirolimus from recessed abluminal grooves at a lower drug and polymer load compared with many contemporary drug-eluting stents, with the aim of reducing delayed vascular healing while maintaining anti-restenotic efficacy.[29][30]
Structural heart and cardiac rhythm management
MicroPort’s structural heart and CRM platforms represent its implantable cardiovascular device businesses focused on valvular heart disease, pacing, and heart failure therapy. The structural heart business is operated through the listed subsidiary MicroPort CardioFlow (02160.HK), which develops transcatheter heart valve implantation systems for the treatment of aortic valve disease.
MicroPort’s CRM business is headquartered in Clamart, France, and was formed through the 2018 acquisition of LivaNova’s CRM division for approximately €190 million.[31] The CRM portfolio includes pacemakers, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT) systems, and associated transvenous leads for the treatment of bradyarrhythmias, ventricular arrhythmias, and heart failure.
In 2025, MicroPort announced a merger of CardioFlow with its CRM business to form a more integrated global cardiovascular implantable device platform.[32]
Orthopedics
MicroPort Orthopedics, based in Arlington, Tennessee, was established through the 2014 acquisition of Wright Medical's OrthoRecon business for $290 million.[33] The product portfolio includes the ADVANCE Medial-Pivot knee system, PROFEMUR hip systems, DYNASTY and TRINITY hip replacement implants, and various trauma fixation devices.
Surgical robotics
MicroPort's surgical robotics business is operated through Shanghai MicroPort MedBot (02252.HK), a separately listed subsidiary that completed its initial public offering in November 2021.[34] Its primary multi-port product is the Toumai Surgical Robot System, a four-arm laparoscopic robot designed for minimally invasive general, thoracic, urological, and gynecological surgery.
Other platforms
Additional business platforms include endovascular implants, neurologic devices, critical care and extracorporeal membrane oxygenation systems (ECMO), minimally invasive urological devices, metabolic and diabetes care technologies, and other specialty medical-device divisions operated through unlisted subsidiaries.
↑Gao, RL (20 May 2013). "A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial". EuroIntervention. 9 (1): 75–83. doi:10.4244/EIJV9I1A12. PMID23685298. S2CID7244124.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
US$793.493Million (2019 Annual) [1]